NCT03960177 2026-01-07
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
11 trialsNCT05022797 2024-05-13
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Terminated
NCT04668768 2024-03-22
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Fox Chase Cancer Center
Phase 2 Suspended
NCT00634504 2022-06-06
LVPK
BTG International Inc.
Phase 1 Completed
NCT01305655 2018-09-28
NOPHOCPG2
Nordic Society for Pediatric Hematology and Oncology
Phase 3 Completed
NCT02022358 2015-06-04
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
University College, London
Phase 2 Terminated
NCT00018967 2015-04-30
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
National Cancer Institute (NCI)
Phase NA Completed
NCT00634322 2014-09-15
High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
BTG International Inc.
Phase 2 Terminated
NCT00219791 2014-09-11
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
BTG International Inc.
Phase 2 Completed
NCT00727831 2014-01-27
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
University College, London
Phase 1/2 Completed
NCT00424645 2012-12-06
Voraxaze for Delayed Methotrexate Clearance
M.D. Anderson Cancer Center
Phase 1/2 Terminated